

Supplementary File

Table S1. Demographic and clinical features in different therapy groups.

Variables	Biologics n=25	*Non-biologic systemic treatment n=31	Non-systemic** treatment n=147	p-value
Age at first rheumatology visit (years), mean ± SD	54.1 ± 13.8	50.8 ± 12.9	49.7 ± 14.2	0.326
Age at diagnosis of psoriasis (years), mean ± SD	38.3 ± 17.9	35.9 ± 17.5	31.6 ± 17.0	0.229
Men	8, 32.0	18, 58.1	64, 43.5	0.139
Smoking (ever)	11/20, 55.0	17/27, 63.0	53/121, 43.8	0.160
BMI, mean ± SD	37.4 ± 7.4	31.8 ± 5.5	30.0 ± 6.3	0.001
Psoriasis duration (years), mean ± SD	15.2 ± 12.9	13.9 ± 10.1	15.9 ± 13.9	0.985
Type of psoriasis				
Plaque	19/22, 86.4	24/24, 96.0	83/93, 89.2	0.809
Pustular	2/22, 9.1	1/25, 4.0	7/93, 7.5	
Others	1/22, 4.5	0	3/93, 3.2	
Duration of MSK symptoms (years), mean ± SD	10.1 ± 14.5	6.7 ± 6.5	5.8 ± 6.2	0.745
Initial symptom type				
Peripheral joint	15/25, 60.0	20/30, 66.7	94/146, 64.4	0.928
Spine	2/25, 8.0	2/30, 6.7	14/146, 9.6	
Peripheral joint + Spine	8/25, 32.0	8/30, 26.7	33/146, 22.6	
Peripheral joint + Enthesis	0	0	3/146, 2.1	
Peripheral joint + Spine + Enthesis	0	0	2/146, 1.4	
The onset of MSK symptoms				
Before the skin manifestations	5/25, 20.0	5/27, 18.5	22/137, 16.1	0.945
At the same time with the skin	1/25, 4.0	1/27, 3.7	3/137, 2.2	
After the skin manifestations	19/25, 76.0	21/27, 77.8	112/137, 81.8	
Type of Arthralgia				
Monoarthralgia	0	2/26, 7.7	5/120, 4.2	0.780
Oligoarthralgia	2/20, 10	3/26, 11.5	12/120, 10.0	
Polyarthralgia	18/20, 90	21/26, 80.8	103/120, 85.8	
TJC at first visit, mean ± SD	5.5 ± 9.3	5.2 ± 7.3	4.5 ± 7.6	0.901
Presence of a swollen joint	8/22, 36.4	14/29, 48.3	60/129, 46.5	0.643
Type of arthritis				
Monoarthritis	1/7, 14.3	2/14, 14.3	7/57, 12.3	0.688
Oligoarthritis	0	3/14, 21.4	14/57, 24.6	
Polyarthritis	6/7, 85.7	9/14, 64.3	36/57, 63.2	
SJC at first visit, mean ± SD	1.4 ± 2.7	1.1 ± 1.8	1.1 ± 2.4	0.792
Enthesitis (ever)	7/18, 38.9	3/22, 13.6	25/88, 28.4	0.188
Dactylitis (ever)	0	2/21, 9.5	22/92, 23.9	0.092
Uveitis (ever)	2/13, 15.4	1/20, 5.0	10/83, 12.0	0.588
Nail involvement (ever)	5/11, 45.5	7/18, 38.9	43/82, 52.4	0.558
ESR at first visit, mean ± SD	8.6 ± 7.9	11.6 ± 9.6	11.6 ± 12.3	0.605
CRP at first visit, mean ± SD	4.7 ± 4.2	5.6 ± 4.0	6.1 ± 8.2	0.245
RF positivity	0	3/20, 15.0	6/75, 8.0	0.325
Anti-CCP positivity	2/10, 20.0	2/15, 13.3	6/54, 11.1	0.737
HLA B27 positivity	1/6, 16.7	1/8, 12.5	16/55, 29.1	0.522

*This group included Methotrexate, Apremilast and vitamin A analogues.

**This group included topical creams/PUVA or no treatment.

BMI: Body Mass index; CCP: cyclic citrullinated peptide; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; HLA: human leukocyte antigen; MSK: musculoskeletal; MTX: methotrexate; RF: rheumatoid factor; SJC: swollen joint count; SD: standard deviation; TJC: tender joint count.

Numbers are given as n/known cases (%), unless stated otherwise.

Table S2. Demographic and clinical features of patients diagnosed with PsA in different therapy groups.

Variables	Biologics n=9	*Non-biologic systemic treatment n=11	**None systemic treatment n=55	p-value
Age at first rheumatology visit (years), mean ± SD	54.1 ± 13.4	44.0 ± 17.3	45.9 ± 13.4	0.255
Age at diagnosis of psoriasis (years), mean ± SD	39.2 ± 14.4	33.6 ± 20.5	28.5 ± 17.0	0.179
Men	5, 55.6	8, 72.7	30, 54.5	0.535
Smoking (ever)	3/7, 42.9	6/10, 60.0	21/45, 46.7	0.712
BMI, mean ± SD	36.0 ± 7.7	35.2 ± 5.1	29.8 ± 6.3	0.032
Psoriasis duration (years), mean ± SD	14.8 ± 10.6	10.3 ± 7.4	14.3 ± 13.5	0.825
Type of psoriasis				
Plaque	7/8, 87.5	8/9, 88.9	31/36, 86.1	0.974
Pustular	1/8, 12.5	1/9, 11.0	5/36, 13.9	
Others	0	0	0	
Duration of MSK symptoms (years), mean ± SD	16.6 ± 21.0	6.3 ± 6.7	4.6 ± 5.4	0.305
Initial symptom type				
Peripheral joint	6/9, 66.7	7/11, 63.6	32/55, 58.2	0.977
Spine	0	1/11, 9.1	5/55, 9.1	
Peripheral joint + Spine	3/9, 33.3	3/11, 27.3	15/55, 27.3	
Peripheral joint + Enthesis	0	0	2/55, 3.6	
Peripheral joint + Spine + Enthesis	0	0	1/55, 1.8	
The onset of MSK symptoms				
Before the skin manifestations	4/9, 44.4	4/11, 36.4	8/54, 14.8	0.171
At the same time with the skin	0	1/11, 9.1	3/54, 5.6	
After the skin manifestations	5/9, 55.6	6/11, 54.5	43/54, 79.6	
Type of Arthralgia				
Monoarthralgia	0	0	0	0.845
Oligoarthralgia	1/8, 12.5	2/9, 22.2	7/45, 15.6	
Polyarthralgia	7/8, 87.5	7/9, 77.8	38/45, 84.4	
TJC at first visit, mean ± SD	12.8 ± 13.0	7.3 ± 7.4	5.5 ± 9.5	0.168
Presence of a swollen joint	7/8, 87.5	9/10, 90.0	42/49, 85.7	0.253
Type of arthritis				
Monoarthritis	1/7, 14.3	0	4/41, 9.8	0.477
Oligoarthritis	0	3/9, 33.3	10/41, 24.4	
Polyarthritis	6/7, 85.7	6/9, 66.7	27/41, 65.9	
SJC at first visit, mean ± SD	3.6 ± 3.7	1.8 ± 2.0	2.3 ± 3.0	0.526
Enthesitis (ever)	3/8, 37.5	2/8, 25.0	12/32, 37.5	0.796
Dactylitis (ever)	0	2/7, 28.6	17/35, 48.6	0.046
Uveitis (ever)	1/7, 14.3	1/6, 16.7	7/31, 22.6	0.860
Nail involvement (ever)	2/3, 66.7	5/9, 55.6	20/28, 71.4	0.676
ESR at first visit, mean ± SD	9.2 ± 8.9	12.7 ± 11.1	10.4 ± 11.9	0.743
CRP at first visit, mean ± SD	5.2 ± 5.8	7.9 ± 4.6	7.0 ± 9.3	0.202
RF positivity	0	0	1/29, 3.4	0.809
Anti-CCP positivity	1/5, 20.0	0	1/22, 4.5	0.336
HLA B27 positivity	1/5, 20.0	1/5, 20.0	9/29, 31.0	0.800

*This group included Methotrexate, Apremilast and vitamin A analogs.

**This group included topical creams/PUVA or no treatment.

BMI: Body Mass index; CCP: cyclic citrullinated peptide; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; HLA: human leukocyte antigen; MSK: musculoskeletal; MTX: methotrexate; RF: rheumatoid factor; SJC: swollen joint count; SD: standard deviation; TJC: tender joint count.

Numbers are given as n/known cases (%), unless stated otherwise.